The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines.
The Biologics Prescribers Collaborative has released findings from a physician’s survey about the FDA’s proposed biosimilar naming guidelines. According to the survey, 80 percent of physicians prefer a meaningful four-letter suffix that notes the biosimilar manufacturer’s name as opposed to a random four-letter suffix.
